MoneyWorks4Me

Wockhardt gets US FDA tentative approval for Olopatadine

01 Jul 2011 Evaluate

Drug firm Wockhardt has received tentative approval from US Food and Drug Administration (USFDA) for marketing 0.1% solution of Olopatadine hydrochloride eye drops, which is used for allergic conjunctivitis. Olopatadine is the generic name for the brand Patanol, marketed in the US by Alcon laboratories Inc, now a subsidiary of Novartis AG.

The patent covering this product is under litigation in the US courts and Wockhardt will launch the product after resolution of the same.

Wockhardt is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalization and biotechnology. The company has a market capitalization of over $1 billion and an annual turnover of $650 million.

Wockhardt Share Price

1885.80 55.65 (3.04%)
21-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1900.90
Dr. Reddys Labs. 1175.00
Cipla 1426.20
Lupin 2193.00
Zydus Lifesciences 1120.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: